J 2011

The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia

RÁZGA, Filip, Zdeněk RÁČIL, Kateřina MACHOVÁ POLÁKOVÁ, Lucie BUREŠOVÁ, Hana KLAMOVA et. al.

Basic information

Original name

The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia

Name in Czech

Prediktivní hodnota exprese genů human organic cation transporter 1 a ABCB1v různých buněčných populacích u pacientů s de novo chronickou myeloidní leukémií

Authors

RÁZGA, Filip (703 Slovakia, guarantor, belonging to the institution), Zdeněk RÁČIL (203 Czech Republic, belonging to the institution), Kateřina MACHOVÁ POLÁKOVÁ (203 Czech Republic), Lucie BUREŠOVÁ (203 Czech Republic, belonging to the institution), Hana KLAMOVA (203 Czech Republic), Daniela ŽÁČKOVÁ (203 Czech Republic, belonging to the institution), Dana DVOŘÁKOVÁ (203 Czech Republic, belonging to the institution), Václava POLÍVKOVÁ (203 Czech Republic), Petr CETKOVSKÝ (203 Czech Republic) and Jiří MAYER (203 Czech Republic, belonging to the institution)

Edition

International Journal of Hematology, 2011, 0925-5710

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Japan

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.268

RIV identification code

RIV/00216224:14740/11:00053607

Organization unit

Central European Institute of Technology

UT WoS

000297204800017

Keywords in English

human organic cation transporter; ABCB1; chronic myelogenous leukemia

Tags

Tags

International impact
Změněno: 12/1/2012 14:44, Mgr. Michal Petr

Abstract

V originále

In this study, we investigated the predictive value of pretreatment mRNA expression levels of hOCT-1 and ABCB1 in different cell populations with regard to the response to therapy at 6 and 12 months of IMA therapy. Expression levels were assessed in peripheral blood (PB) leukocytes (LEU, n = 30), polymorphonuclear cells (PMNC, n = 23), and mononuclear cells (MNC, n = 21) of PB LEU obtained from 30 patients with de novo chronic myelogenous leukemia (CML). Moreover, the available bone marrow cells (BM) were also included and analyzed (BM, n = 11). The PB and BM samples were obtained, processed, and analyzed as previously described. Responses to therapy were classified according the European LeukemiaNet 2009 (ELN) criteria: responders show an optimal response at 6 months and 12 months, while non-responders reflect a suboptimal response or therapy failure. The assessed pretreatment expression levels were stratified into two groups according to the median-a low-mRNA expression group below the median and a high-mRNA expression group equal to or above the median. The statistical evaluation of the data obtained was performed using the Fisher’s exact tests and summarized in Table 2.

Links

MSM0021622430, plan (intention)
Name: Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie
Investor: Ministry of Education, Youth and Sports of the CR, Functional and molecular characteristics of cancer and normal stem cells - identification of targets for novel therapeutics and therapeutic strategies